SION PE Ratio & Valuation,Is SION Overvalued

SION Relative Valuation

SION's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SION is overvalued; if below, it's undervalued.

Historical Valuation

Sionna Therapeutics Inc (SION) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.54. The fair price of Sionna Therapeutics Inc (SION) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：36.60

Fair

-19.14

-13.55

EV/EBITDA

Sionna Therapeutics Inc. (SION) has a current EV/EBITDA of -13.55. The 5-year average EV/EBITDA is -7.55. The thresholds are as follows: Strongly Undervalued below -15.88, Undervalued between -15.88 and -11.72, Fairly Valued between -3.38 and -11.72, Overvalued between -3.38 and 0.78, and Strongly Overvalued above 0.78. The current Forward EV/EBITDA of -13.55 falls within the Undervalued range.

-13.39

EV/EBIT

Sionna Therapeutics Inc. (SION) has a current EV/EBIT of -13.39. The 5-year average EV/EBIT is -7.47. The thresholds are as follows: Strongly Undervalued below -15.73, Undervalued between -15.73 and -11.60, Fairly Valued between -3.34 and -11.60, Overvalued between -3.34 and 0.79, and Strongly Overvalued above 0.79. The current Forward EV/EBIT of -13.39 falls within the Undervalued range.

0.00

Sionna Therapeutics Inc. (SION) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-19.67

P/OCF

Sionna Therapeutics Inc. (SION) has a current P/OCF of -19.67. The 5-year average P/OCF is -15.24. The thresholds are as follows: Strongly Undervalued below -47.86, Undervalued between -47.86 and -31.55, Fairly Valued between 1.06 and -31.55, Overvalued between 1.06 and 17.37, and Strongly Overvalued above 17.37. The current Forward P/OCF of -19.67 falls within the Historic Trend Line -Fairly Valued range.

-18.94

P/FCF

Sionna Therapeutics Inc. (SION) has a current P/FCF of -18.94. The 5-year average P/FCF is -11.11. The thresholds are as follows: Strongly Undervalued below -22.39, Undervalued between -22.39 and -16.75, Fairly Valued between -5.47 and -16.75, Overvalued between -5.47 and 0.17, and Strongly Overvalued above 0.17. The current Forward P/FCF of -18.94 falls within the Undervalued range.

Sionna Therapeutics Inc (SION) has a current Price-to-Book (P/B) ratio of 5.42. Compared to its 3-year average P/B ratio of 2.57 , the current P/B ratio is approximately 110.60% higher. Relative to its 5-year average P/B ratio of 2.57, the current P/B ratio is about 110.60% higher. Sionna Therapeutics Inc (SION) has a Forward Free Cash Flow (FCF) yield of approximately -3.52%. Compared to its 3-year average FCF yield of -6.77%, the current FCF yield is approximately -47.94% lower. Relative to its 5-year average FCF yield of -6.77% , the current FCF yield is about -47.94% lower.

5.42

P/B

Median3y

2.57

Median5y

2.57

-3.52

FCF Yield

Median3y

-6.77

Median5y

-6.77

Competitors Valuation Multiple

The average P/S ratio for SION's competitors is 381.43, providing a benchmark for relative valuation. Sionna Therapeutics Inc Corp (SION) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SION increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of SION in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Sionna Therapeutics Inc (SION) currently overvalued or undervalued?

What is Sionna Therapeutics Inc (SION) fair value?

SION's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sionna Therapeutics Inc (SION) is between to according to relative valuation methord.

How does SION's valuation metrics compare to the industry average?

The average P/S ratio for SION's competitors is 381.43, providing a benchmark for relative valuation. Sionna Therapeutics Inc Corp (SION) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Sionna Therapeutics Inc (SION) as of Jan 09 2026?

As of Jan 09 2026, Sionna Therapeutics Inc (SION) has a P/B ratio of 5.42. This indicates that the market values SION at 5.42 times its book value.

What is the current FCF Yield for Sionna Therapeutics Inc (SION) as of Jan 09 2026?

As of Jan 09 2026, Sionna Therapeutics Inc (SION) has a FCF Yield of -3.52%. This means that for every dollar of Sionna Therapeutics Inc’s market capitalization, the company generates -3.52 cents in free cash flow.

What is the current Forward P/E ratio for Sionna Therapeutics Inc (SION) as of Jan 09 2026?

As of Jan 09 2026, Sionna Therapeutics Inc (SION) has a Forward P/E ratio of -19.14. This means the market is willing to pay $-19.14 for every dollar of Sionna Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sionna Therapeutics Inc (SION) as of Jan 09 2026?

As of Jan 09 2026, Sionna Therapeutics Inc (SION) has a Forward P/S ratio of 0.00. This means the market is valuing SION at $0.00 for every dollar of expected revenue over the next 12 months.

SION Valuation